Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy
Abstract Background Lung adenocarcinoma (LUAD) is a major contributor to cancer mortality and exhibits high intratumoral heterogeneity. The functional role of SPATS2 in LUAD remains poorly defined. Methods We integrated transcriptomic data from TCGA, GTEx, and GEO databases to evaluate SPATS2 expres...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03179-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342217804578816 |
|---|---|
| author | Maorong Teng Fangtao Yan Jingping Shang Xiaohua Sun Yahui Wang Jian Shen |
| author_facet | Maorong Teng Fangtao Yan Jingping Shang Xiaohua Sun Yahui Wang Jian Shen |
| author_sort | Maorong Teng |
| collection | DOAJ |
| description | Abstract Background Lung adenocarcinoma (LUAD) is a major contributor to cancer mortality and exhibits high intratumoral heterogeneity. The functional role of SPATS2 in LUAD remains poorly defined. Methods We integrated transcriptomic data from TCGA, GTEx, and GEO databases to evaluate SPATS2 expression patterns and their associations with clinical features and prognosis in LUAD. Genomic analyses were performed to assess copy number variations, mutation correlations, and tumor mutation burden (TMB). Functional enrichment analyses (GSEA, GSVA) and immune infiltration profiling (CIBERSORT, ESTIMATE, TIP) were conducted to explore the biological and immunological roles of SPATS2. Single-cell RNA sequencing data from the TISCH database (GSE131907) were used to determine SPATS2 expression in tumor microenvironment (TME) cell subsets. In vitro experiments using siRNA-SPATS2 in A549 cells were performed to assess mitochondrial function. Results SPATS2 expression was significantly elevated in LUAD tissues and correlated with copy number amplification and increased TMB. High SPATS2 levels were associated with advanced stage, lymph node metastasis, and worse overall survival. Functional analyses revealed enrichment in cell cycle, DNA repair, and metabolic pathways. Immune profiling indicated that SPATS2 modulates immune infiltration, with higher expression linked to increased infiltration of macrophages and Tregs, and reduced stromal and immune scores. Single-cell data showed SPATS2 expression was highest in endothelial and plasma cells. Knockdown of SPATS2 impaired mitochondrial membrane potential and reduced ROS levels in A549 cells. Conclusion SPATS2 is a potential prognostic biomarker and therapeutic target in LUAD. Its role in tumor progression, immune remodeling, and mitochondrial function warrants further investigation in personalized therapy development. |
| format | Article |
| id | doaj-art-4590b1a564354d7c8cfaa9be978b7f86 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-4590b1a564354d7c8cfaa9be978b7f862025-08-20T03:43:27ZengSpringerDiscover Oncology2730-60112025-08-0116111710.1007/s12672-025-03179-7Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapyMaorong Teng0Fangtao Yan1Jingping Shang2Xiaohua Sun3Yahui Wang4Jian Shen5Department of General Practice, the Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityDepartment of Pulmonary and Critical Care Medcine, Chengdu Institute of Respiratory Health, The Third People’s Hospital of ChengduDepartment of General Practice, the Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityDepartment of General Practice, the Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityDepartment of General Practice, the Affiliated Taizhou People’s Hospital of Nanjing Medical UniversityDepartment of Pulmonary and Critical Care Medcine, Chengdu Institute of Respiratory Health, The Third People’s Hospital of ChengduAbstract Background Lung adenocarcinoma (LUAD) is a major contributor to cancer mortality and exhibits high intratumoral heterogeneity. The functional role of SPATS2 in LUAD remains poorly defined. Methods We integrated transcriptomic data from TCGA, GTEx, and GEO databases to evaluate SPATS2 expression patterns and their associations with clinical features and prognosis in LUAD. Genomic analyses were performed to assess copy number variations, mutation correlations, and tumor mutation burden (TMB). Functional enrichment analyses (GSEA, GSVA) and immune infiltration profiling (CIBERSORT, ESTIMATE, TIP) were conducted to explore the biological and immunological roles of SPATS2. Single-cell RNA sequencing data from the TISCH database (GSE131907) were used to determine SPATS2 expression in tumor microenvironment (TME) cell subsets. In vitro experiments using siRNA-SPATS2 in A549 cells were performed to assess mitochondrial function. Results SPATS2 expression was significantly elevated in LUAD tissues and correlated with copy number amplification and increased TMB. High SPATS2 levels were associated with advanced stage, lymph node metastasis, and worse overall survival. Functional analyses revealed enrichment in cell cycle, DNA repair, and metabolic pathways. Immune profiling indicated that SPATS2 modulates immune infiltration, with higher expression linked to increased infiltration of macrophages and Tregs, and reduced stromal and immune scores. Single-cell data showed SPATS2 expression was highest in endothelial and plasma cells. Knockdown of SPATS2 impaired mitochondrial membrane potential and reduced ROS levels in A549 cells. Conclusion SPATS2 is a potential prognostic biomarker and therapeutic target in LUAD. Its role in tumor progression, immune remodeling, and mitochondrial function warrants further investigation in personalized therapy development.https://doi.org/10.1007/s12672-025-03179-7SPATS2Lung adenocarcinomaPrognostic biomarkerTumor immune microenvironmentSingle-cell RNA sequencing |
| spellingShingle | Maorong Teng Fangtao Yan Jingping Shang Xiaohua Sun Yahui Wang Jian Shen Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy Discover Oncology SPATS2 Lung adenocarcinoma Prognostic biomarker Tumor immune microenvironment Single-cell RNA sequencing |
| title | Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy |
| title_full | Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy |
| title_fullStr | Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy |
| title_full_unstemmed | Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy |
| title_short | Targeting SPATS2 in lung adenocarcinoma: implications for prognosis and immune-based therapy |
| title_sort | targeting spats2 in lung adenocarcinoma implications for prognosis and immune based therapy |
| topic | SPATS2 Lung adenocarcinoma Prognostic biomarker Tumor immune microenvironment Single-cell RNA sequencing |
| url | https://doi.org/10.1007/s12672-025-03179-7 |
| work_keys_str_mv | AT maorongteng targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy AT fangtaoyan targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy AT jingpingshang targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy AT xiaohuasun targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy AT yahuiwang targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy AT jianshen targetingspats2inlungadenocarcinomaimplicationsforprognosisandimmunebasedtherapy |